I would surmise that, as usual, Diwan doesn't have any way to fund an actual clinical trial.
The Measles outbreak is trending in the news with all the unvaccinated yahoos spreading it widely, and applying for an Orpha Drug status keeps the company sounding relevant within the US. Monkeypox is 'out of sight' in Africa for the most part. Getting the attention from the market for Measles helps delay a complete collapse of share prices for the short term.
Market Data 
Markets 
AI
